Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | EBP | Q15125 | 2/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4169169 | 0.99 | TRPV6 (0.58) | TRPV6SIGMAR1KCNH2EBPTMEM97 | |
| SCHEMBL18713082 | 0.83 | TRPV6 (0.57) | TRPV6HRH3 | |
| SCHEMBL18713087 | 0.80 | TRPV6 (0.57) | TRPV6SIGMAR1HRH3 | |
| SCHEMBL20413614 | 0.79 | TRPV6 (0.56) | TRPV6SIGMAR1HRH3 | |
| SCHEMBL23589183 | 0.79 | HRH3 (0.67) | TRPV6HRH3 | |
| SCHEMBL29259746 | 0.78 | TRPV6 (0.56) | TRPV6SIGMAR1HRH3 | |
| SCHEMBL20071088 | 0.78 | CHKA (0.59) | TRPV6HRH3 | |
| SCHEMBL14486572 | 0.78 | MEN1 (0.50) | TRPV6 | |
| SCHEMBL209098 | 0.77 | TRPV6 (0.55) | TRPV6HRH3 | |
| SCHEMBL20804834 | 0.77 | DRD4 (0.56) | TRPV6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2009-01-15 | — | — | US | claimed |
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2009-01-15 | — | — | US | disclosed |
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2009-01-15 | — | — | US | disclosed |
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2009-01-15 | — | — | US | disclosed |
| EP-1981849-A1 | HETEROCYCLIC COMPOUNDS | LEK Pharmaceuticals D.D. (SI) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007073935-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007073935-A1 | HETEROCYCLIC COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018118-A1 | HETEROCYCLIC COMPOUNDS | CYP51A1, DHCR7, LSS | TRPV6 1740/4885SIGMAR1 1948/4885KCNH2 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.